Medical implantable device and method of use

The medical device with a polymer matrix and bioadhesive coating addresses migration issues by integrating with tissue, providing both temporary and permanent fixation, ensuring effective treatment without additional procedures.

JP7954154B2Active Publication Date: 2026-11-19BOSTON SCIENTIFIC SCIMED INC
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
JP2023555802
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2021-03-22
Filing Date
2022-03-21
Publication Date
2026-11-19
Estimated Expiration
2042-03-21

AI Technical Summary

Technical Problem

Medical devices, such as stents, tend to migrate from their target implantation site due to their compressible and flexible configuration, influenced by peristalsis and smooth environments, reducing effectiveness and causing health complications, and current securing methods often require additional procedures for tool removal.

Method used

A medical device with a polymer matrix and bioadhesive coating, featuring a temporary and permanent securing mechanism, where the polymer matrix allows tissue growth and the bioadhesive coating provides initial fixation, followed by tissue integration, ensuring long-term adherence without auxiliary tools.

Benefits of technology

The device effectively minimizes migration by promoting tissue integration, reducing the need for additional procedures and enhancing treatment efficacy by maintaining device position at the target site.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007954154000001
    Figure 0007954154000001
  • Figure 0007954154000002
    Figure 0007954154000002
  • Figure 0007954154000003
    Figure 0007954154000003
Patent Text Reader

Abstract

A medical device comprising a body and a polymeric matrix covering the body, the polymeric matrix comprising a plurality of fibers defining a plurality of pores to permit tissue growth therethrough, and a bioadhesive coating at least partially covering the polymeric matrix.
Need to check novelty before this filing date? Find Prior Art

Description

TECHNICAL FIELD

[0001] Various aspects of the present disclosure relate generally to medical implant systems, devices, and associated methods. For example, the present disclosure includes systems, devices, and related methods for securing an implantable device to a target treatment site in a subject. BACKGROUND ART

[0002] Medical devices such as stents designed for implantation in a subject may gradually migrate from the target location within the subject where the device was initially placed. The tendency of a medical device to migrate can be caused by the compressible and / or flexible configuration of the device, and can be influenced by peristalsis (e.g., involuntary contraction and relaxation of muscles in the esophagus, intestine, colon, etc.) or the generally smooth environment at the target location. Migration of the implantable device may minimize the effectiveness of the device in treating the target location, and may cause further health complications to the subject. Some procedures may involve securing the implantable device at the target location through the use of auxiliary tools such as sutures or tapes to reduce migration. However, these approaches generally require subsequent removal of the auxiliary tools from the target location, thereby requiring the subject to undergo additional procedures. Devices and methods for securing an implantable device within a subject that do not require the use of auxiliary tools to secure the device at the target location may be limited. SUMMARY OF THE INVENTION

[0003] Aspects of the present disclosure relate, inter alia, to systems, devices, and methods for treating a target treatment site using an implantable device that provides a plurality of securing mechanisms. For example, the device may include a first temporary securing mechanism and a second permanent securing mechanism. Each of the aspects disclosed herein may include one or more of the features described in connection with any of the other disclosed aspects.

[0004] According to at least one example, the medical device comprises a body, a polymer matrix covering the body which includes a plurality of fibers that define a plurality of pores and allow tissue growth through them, and a bioadhesive coating that covers at least partially the polymer matrix.

[0005] Any one of the medical devices described herein may include any of the following features: The bioadhesive coating may be biodegradable. The multiple fibers may have a diameter in the range of about 300 nm to about 700 nm. The bioadhesive coating may be chemically bonded to the multiple fibers. The body may include an expandable stent having multiple support members and multiple openings between adjacent support members, wherein the multiple fibers are positioned on the multiple support members. The multiple fibers may be electrospun on the body. The medical device may include silicone between at least a portion of the body and a polymer matrix. The bioadhesive coating may include a polysaccharide crosslinked with a linker molecule. The polysaccharide may include chitosan. The linker molecule may include polyethylene glycol. The polymer matrix may include a fluoropolymer. The body may comprise a biocompatible metal or metal alloy configured to move from a compressed state to an expanded state. For example, in the compressed form, the body may have a first length and a first diameter, and in the expanded form, the body may have a second length greater than the first length and a second diameter smaller than the first diameter.

[0006] In another example, the medical device comprises an expandable body including a plurality of openings, a polymer matrix containing a plurality of fibers arranged along the outer surface of the body and within at least a portion of the plurality of openings, and a biodegradable bioadhesive coating chemically bonded to the polymer matrix. The medical device may further include silicone between at least a portion of the body and the polymer matrix. The bioadhesive coating may contain chitosan. The chitosan may be crosslinked. The polymer matrix may contain a thermoplastic polymer.

[0007] A treatment method is also disclosed. For example, the method may include a step of treating a target by delivering a medical device to a target tissue, the medical device comprising an expandable body, a polymer matrix containing a plurality of fibers on the body, and a bioadhesive coating that at least partially covers the polymer matrix, the bioadhesive coating adhering the polymer matrix and the body to the tissue, and the medical device promoting cell growth from the tissue through the bioadhesive coating and polymer matrix. The bioadhesive coating may maintain contact with the tissue for, for example, 24 hours to 6 months.

[0008] It should be understood that both the general description above and the detailed description below are illustrative and descriptive, and do not limit the claimed invention. [Brief explanation of the drawing]

[0009] The accompanying drawings incorporated herein and constituting part of herein illustrate exemplary embodiments of this disclosure and serve to illustrate the principles of this disclosure together with the description. [Figure 1] Figure 1 is a perspective view of an exemplary medical device including first and second fixing mechanisms according to an aspect of this disclosure. [Figure 2] Figure 2 is a partially enlarged view of the first and second fixing mechanisms of the medical device shown in Figure 1, according to an aspect of this disclosure. [Figure 3] Figure 3 is a partial perspective view of the medical device of Figure 1, fixed to a target therapeutic site, according to an aspect of this disclosure. [Modes for carrying out the invention]

[0010] For example, implantable medical devices having features to facilitate placement within a patient in order to minimize device movement are included herein. Target therapeutic sites for implanting the implantable medical device may include tissue walls such as the esophagus or other parts of the patient's gastrointestinal system. The devices herein may include features to prevent the device from moving away from the initial target therapeutic site where it was initially implanted.

[0011] Embodiments of this disclosure include systems, apparatus, and methods for implanting an implantable medical device at a target therapeutic site within a subject (e.g., a patient). In embodiments, access to the patient's esophagus includes intraluminal placement of the medical device within the target therapeutic site. Placement of the medical device may be via a catheter, scope (such as an endoscope, bronchoscope, or colonoscope), tube, or sheath, and may be inserted into an anatomical passage via a natural opening or laparoscope. The opening may be, for example, the nose, mouth, or anus, and placement may be in any part of the GI duct, including the esophagus, stomach, duodenum, large intestine, or small intestine. Placement may also be in the GI duct, other body lumen, or other organ or other body space accessible via an opening within the body, including via laparoscope. This disclosure is not limited to any specific medical procedure or therapeutic site within the body.

[0012] Hereinafter, aspects of this disclosure are referenced in detail, examples of which are shown in the accompanying drawings. Wherever possible, the same or similar reference numbers are used throughout the drawings to refer to identical or similar parts. The term “distal” refers to the part of the device furthest from the user when the device is introduced into the patient. Conversely, the term “proximal” refers to the part of the device closest to the user when the device is placed within the object. Where used herein, the terms “comprises,” “comprising,” or any other variation thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or device containing a list of elements does not necessarily contain only those elements, but may contain other elements not expressly enumerated or specific to such process, method, article, or device. The term “exemplary” is used in the sense of “example” rather than “ideal.” Where used herein, the terms “about,” “substantially,” and “approximately” indicate a range of values ​​within + / - 5% of the stated value.

[0013] Embodiments of this disclosure may relate to devices and methods for performing and / or treating various medical procedures on the large intestine (colon), small intestine, cecum, esophagus, any other part of the gastrointestinal tract, and / or any other appropriate anatomical structure of a patient (collectively referred to herein as “Target Therapy Sites”). As stated above, this disclosure is not limited to any particular medical device or method, and embodiments of this disclosure may be used in conjunction with any appropriate medical tool and / or medical method at any appropriate site in the body. Various examples described herein include single-use or disposable medical devices.

[0014] Figure 1 shows an exemplary medical device 100 according to one or more examples of the present disclosure. The medical device 100 comprises a body 102 having a longitudinal length defined between a first end 104 and a second end 106. One or more of the first end 104 or the second end 106 may optionally be radially flared outward with respect to the cross-sectional shape of the body 102. The body 102 may be flexible and may be configured to expand axially and / or radially when transitioning from a compressed state to an expanded state. In other words, the body 102 may have a first length and a first diameter when in the first compressed state. The body 102 may further have a second length and a second diameter when in the second expanded state. The second length and / or second diameter may each be greater than the first length and / or first diameter. Optionally, the second length may be greater than the first length, and the second diameter may be greater than the first diameter.

[0015] The body 102 may include a lumen defined between a first end 104 and a second end 106, a first opening 105 at the first end 104, and a second opening 107 at the second end 106. The first opening 105 and the second opening 107 may communicate with each other through the lumen of the body 102. As shown, the body 102 includes an expandable stent assembly having a plurality of support members 108 and a plurality of openings 110 defined between adjacent support members 108. The body 102 may be formed from a variety of suitable materials having flexible properties, such as biocompatible metals, metal alloys, shape memory materials, etc. The medical device 100 may further include a biocompatible matrix 120 disposed on at least a portion of the body 102 between the first end 104 and the second end 106, the matrix 120 may include one or more polymers. In some embodiments, the polymer matrix 120 may be positioned over a substantial portion of the longitudinal length of the body 102 such that the polymer matrix 120 includes a longitudinal length substantially similar to that of the body 102. In other embodiments, the polymer matrix 120 may be positioned over a portion of the body 102 that is less than the longitudinal length of the body 102 such that one or more portions of the body 102 are not covered by the polymer matrix 120.

[0016] As shown in Figure 2, the polymer matrix 120 may include a plurality of fibers 122 defining a plurality of pores 124 (e.g., gaps). The plurality of fibers 122 may be arranged on a plurality of support members 108 and a plurality of openings 110 of the body 102, for example, to provide a porous matrix on the body 102. Each fiber of the plurality of fibers 122 may have a diameter in the range of about 100 nanometers (nm) to about 900 nm, for example, about 300 nm to about 700 nm, about 230 nm to about 550 nm, or about 450 nm to about 650 nm. The thickness of the polymer matrix 120 may range from at least 1 micron (μm) to at least 1 millimeter (mm), for example, in the range of approximately 1.5 μm to approximately 850 μm, approximately 5 μm to approximately 10 μm, approximately 50 μm to approximately 250 μm, approximately 350 μm to approximately 750 μm, approximately 450 μm to approximately 600 μm, approximately 650 μm to approximately 950 μm, or approximately 300 μm to approximately 550 μm. Each fiber 122 may have the same diameter, or multiple fibers 122 may contain fibers of different dimensions. It should be understood that the diameter of the fiber 122 can at least partially determine the size of the pores 124 defined between adjacent fibers 122.

[0017] Because it is porous, the polymer matrix 120 can allow one or more materials to pass through it. For example, as will be described in more detail herein, the polymer matrix 120 can allow tissue growth between multiple fibers 122 and through multiple pores 124. The dimensions of the multiple pores 124 can at least partially determine the rate of tissue growth through the polymer matrix 120. The dimensions of the multiple fibers 122 (e.g., thickness, diameter, etc.) can at least partially determine the rate of tissue growth through the polymer matrix 120. In some embodiments, the multiple fibers 122 may be sintered to enhance the material composition of the multiple fibers 122 and to reduce the fragility of the polymer matrix 120. According to some examples herein, the porosity of the polymer matrix 120 may remain substantially consistent when the multiple fibers 122 are sintered. Furthermore, for example, the porosity of the polymer matrix 120 may be fine-tuned to allow proper decomposition and cell growth infiltration between the multiple fibers 122 and through the multiple pores 124.

[0018] The polymer matrix 120 may be formed on the body 102 by any suitable technique, including, for example, electrospinning. For example, the polymer matrix 120 may be formed by electrospinning a polymer material onto the body 102. Exemplary polymer materials include, but are not limited to, thermoplastic polymers containing fluoropolymers, which may be electrospinned while in the form of a liquid solution. The material may be delivered using high electrical force so that the material can be deposited on the outside of the body 102 in a random, asymmetric, and / or irregular pattern. The solvent in the liquid solution may evaporate, and polymer chains may be formed, for example, mechanically entangled. The resulting structure may include a plurality of fibers 122 deposited on the body 102. In some embodiments, the polymer matrix 120 may include polyvinylidene fluoride, polyvinylidene difluoride (PVDF), and / or hexafluoropropylene (HFP).

[0019] As shown in Figure 2, the multiple fibers 122 may be intertwined with each other on the multiple support members 108. It should be understood that the multiple fibers 122 may be further intertwined with the outer surface of the body 102 in order to fix the polymer matrix 120 to the body 102. For example, the medical device 100 may include a material between the body 102 and the multiple fibers 122, for example, a material arranged as one or more outer layers along the outer surface of the body 102. The multiple fibers 122 may be mixed with the material of the outer layers. The outer layers may include a polymer such as silicone. Therefore, during the electrospinning process that generates the polymer matrix 120 on the body 102, the material electrospun on the body 102 (e.g., a fluoropolymer) may be mechanically intertwined with the outer layers.

[0020] The outer layer may be positioned between at least a portion of the body 102 and the polymer matrix 120. For example, the outer layer silicone or other suitable polymer material may be positioned within at least a portion of the multiple openings 110 between the multiple support members 108, and the multiple fibers 122 may be deposited on the multiple support members 108 and / or the multiple openings 110. To minimize the constraints on the flexibility of the body 102, the multiple fibers 122 may be concentrated on the multiple support members 108 during the electrospinning process of the polymer matrix 120. Furthermore, the multiple fibers 122 may be selectively guided onto the multiple support members 108 during the electrospinning process to maintain the outline of the multiple openings 110 defined between them. Once the polymer matrix 120 is formed along the outside of the body 102, the polymer matrix 120 may provide and maintain a barrier around the lumen of the body 102. As described in detail herein, the polymer matrix 120 may provide a first long-term (e.g., permanent) fixation mechanism for immobilizing the medical device 100 to a target therapeutic site within the object.

[0021] The medical device 100 may further include a bioadhesive coating 130 placed on the polymer matrix 120 and at least partially covering the polymer matrix 120. The bioadhesive coating 130 may be chemically bonded to the polymer matrix 120. Thus, the polymer matrix 120 may be placed between the bioadhesive coating 130 and the body 102 so that the bioadhesive coating 130 is separated from the body 102 by the polymer matrix 120. The bioadhesive coating 130 may contain biodegradable materials so that the bioadhesive coating 130 may be reabsorbed or otherwise decomposed after a certain period of time. As will be described in more detail herein, the bioadhesive coating 130 may maintain contact with the target therapeutic site (e.g., tissue) for a desired amount of time, which may depend on the chemical properties and / or thickness of the bioadhesive coating 130. For example, the bioadhesive coating 130 can maintain contact with the target treatment site for approximately 24 hours to approximately 6 months, such as approximately 3 days to approximately 1 week, approximately 1 week to approximately 6 weeks, approximately 1 month to approximately 3 months, or approximately 2 months to approximately 5 months. The degradation time can be controlled by various factors, including, for example, the properties of the biodegradable material and / or the amount (e.g., thickness) of the bioadhesive coating 130 on the polymer matrix 120. The thickness of the bioadhesive coating 130 on the polymer matrix 120 may be in the range of at least approximately 1 μm to at least approximately 1 mm, for example, approximately 1.5 μm to approximately 850 μm, approximately 5 μm to approximately 10 μm, approximately 50 μm to approximately 250 μm, approximately 350 μm to approximately 750 μm, approximately 450 μm to approximately 600 μm, approximately 650 μm to approximately 950 μm, or approximately 300 μm to approximately 550 μm. Furthermore, the bioadhesive coating 130 may be chemically modified on the outer surface of the polymer matrix 120.

[0022] Exemplary materials suitable for the bioadhesive coating 130 include, but are not limited to, polysaccharides such as chitosan. The polysaccharide may be crosslinked with a linker molecule. Examples of such linker molecules include polyethylene glycol (PEG). PEG may provide a hydrophilic scaffold along the polymer matrix 120 and may function as an anchor for the bioadhesive coating 130 to adhere to the polymer matrix 120. The hydrophilic properties of PEG may provide adhesive ability for fixing the bioadhesive coating 130 to the polymer matrix 120. Other suitable materials for the bioadhesive coating 130 include, but are not limited to, chitosan which may be modified with thiol groups, thiol-modified PEG, and polymers such as oxidized cellulose. The bioadhesive coating 130 may have hemostatic properties to simulate a healing response from a target treatment site (e.g., tissue) when in contact with it. In other words, the bioadhesive coating 130 can treat damage at a target treatment site, such as wounds, massive bleeding, damaged tissue, and bleeding. The bioadhesive coating 130 can function as a wound dressing to suppress excessive bleeding and / or promote rapid healing. In addition, the bioadhesive coating 130 may have adhesive properties that allow the main body 102 to be fixed to the target treatment site.

[0023] As described above, the bioadhesive coating 130 can be chemically bonded to the polymer matrix 120, including via linker molecules. Accordingly, linker molecules (e.g., PEG) may be crosslinked with the plurality of fibers 122 to facilitate the connection between the bioadhesive coating 130 and the polymer matrix 120. In some examples, the linker molecules may be entangled with the polymer chains of the polymer matrix 120 as the plurality of fibers 122 are formed on the body 102. In some examples, the bioadhesive coating 130 may be prepared using plasma to crosslink the polysaccharide and the linker molecules. As described in detail herein, the bioadhesive coating 130 can provide a second temporary securing mechanism for securing the medical device 100 to a target treatment site within a subject.

[0024] According to some aspects of the present disclosure, the plurality of fibers 122 may be selectively deposited on the body 102 so as to control the securing properties of the medical device 100 to the target treatment site. For example, the plurality of fibers 122 may be deposited along one or more regions of the body 102, thereby controlling the area of tissue ingrowth into the medical device 100 to one or more specific regions. As described above, the bioadhesive coating 130 may adhere to the surface area of the polymer matrix 120, such that the medical device 100 can include the bioadhesive coating 130 along one or more regions of the body 102 when the plurality of fibers 122 are selectively deposited on the body 102.

[0025] Referring now to Figure 3, an exemplary use of the medical device 100 for treating a target treatment site (e.g., tissue) within a subject is illustrated. It should be understood that the medical device 100 may be positioned at the target treatment site through the use of a medical instrument (e.g., an endoscope) that is inserted through the subject's body and advanced toward the target treatment site. It should be understood that the medical device 100 of the present disclosure may be used at various locations (target treatment sites) within a subject's body, including but not limited to the gastrointestinal tract, organs, or other tissues. In the example shown in Figure 3, the target treatment site includes a tissue wall 12 within the subject's body 10, and the tissue wall 12 has a mucus layer 14 disposed along the exterior of the tissue wall 12. According to some examples herein, the bioadhesive coating 130 of the medical device 100 may have a positive charge that is complementary to the negative charge of the mucus layer 14.

[0026] Upon reaching the tissue wall 12, the medical device 100 may be transluminally inserted via the medical instrument and deployed at the tissue wall 12 therefrom. One or more tools 50, such as a guide wire, may be received through the lumen of the body 102 to facilitate advancing the medical device 100 toward the tissue wall 12. In some embodiments, the bioadhesive coating 130 may provide a smooth outer atraumatic surface to facilitate passage of the medical device 100 through the subject 10 and / or prevent damage to the tissue wall 12 by the polymer matrix 120 and / or the body 102. The medical device 100 may be pressed against the tissue wall 12 such that the bioadhesive coating 130 contacts the mucus layer 12. With the body 102 having a flexible configuration, the medical device 100 can conform to the contour of the tissue wall 12.

[0027] When the bioadhesive coating 130 is positively charged and the mucous layer 14 is negatively charged, the bioadhesive coating 130 is attracted to the mucous layer 14, forming a chemical bond with the tissue surface, thereby fixing the medical device 100 to the tissue wall 12. The bioadhesive coating 130 can maintain the medical device 100 against the tissue wall 12 for at least a minimum duration until the bioadhesive coating 130 is reabsorbed or otherwise decomposed. Thus, the bioadhesive coating 130 can function as a tissue adhesion mechanism to temporarily fix the medical device 100 to the tissue wall 12 and prevent the medical device 100 from moving away from the target treatment site. Furthermore, while the bioadhesive coating 130 remains in contact with the tissue wall 12, the hemostatic properties of the bioadhesive coating 130 can further promote the healing of the tissue wall 12.

[0028] Referring further to Figure 3, when the bioadhesive coating 130 adheres the medical device 100 to the mucus layer 14, the bioadhesive coating 130 can promote tissue growth from the tissue wall 12 through the polymer matrix 120. In other words, by maintaining the polymer matrix 120 in close proximity to the tissue wall 12, the bioadhesive coating 130 can allow tissue cells from the tissue wall 12 to grow through the bioadhesive coating 130 into the multiple pores 124. The tissue cells become entangled with the multiple fibers 122, thereby preventing the medical device 100 from moving away from the target therapeutic site by fixing the medical device 100 to the tissue wall 12. In other words, the multiple pores 124 can function as sites that enable tissue growth into the polymer matrix 120. The bioadhesive coating 130 maintains the medical device 100 against the tissue wall 14 through binding with the mucus layer 14, thereby giving tissue cells sufficient time to grow through the polymer matrix 120.

[0029] Furthermore, as described above, the size of the multiple pores 124 can at least partially control the growth rate of tissue cells through the polymer matrix 120, and the diameter of the multiple fibers 122 can at least partially determine the size of the multiple pores 124. Moreover, the diameter of the multiple fibers 122 may correspond to or correlate with the minimum force required to disengage the medical device 100 from the target therapeutic site. In other words, the multiple fibers 122 may be sized and / or shaped such that they provide the medical device 100 with sufficient mechanical strength to prevent it from moving away from the target therapeutic site. For example, the minimum pull-out force required to move the medical device 100 away from the target therapeutic site may at least partially be associated with the size and / or shape of the multiple fibers 122. Thus, the diameter of the multiple fibers 122 can at least partially contribute to preventing the medical device 100 from being unintentionally released from the tissue wall 12.

[0030] Referring further to Figure 3, even when the bioadhesive coating 130 is decomposed, the medical device 100 may remain attached to the tissue wall 12 through the engagement of the polymer matrix 120 with the tissue wall 12. Therefore, even if the bioadhesive coating 130 is removed from between the polymer matrix 120 and the tissue wall 12, the polymer matrix 120 and the body 102 may remain attached to the tissue wall 12 in response to tissue cell growth through the polymer matrix 120. The medical device 100 may be designed to treat stenosis in a body lumen defined by the tissue wall 12 and / or to provide a fluid pathway for substances (e.g., fluids, digested material, etc.) to flow through the body 102 after an invasive medical procedure. By providing a physical barrier between the body 102 and the tissue wall 12, the polymer matrix 120 can ensure that the fluid pathway through the body 102 is preserved. Furthermore, the polymer matrix 120 can facilitate the removal of the medical device 100 upon completion of the procedure. For example, the polymer matrix 120 may reduce the surface area of ​​the main body 102 that can be fixed to the tissue wall 12, thereby allowing the medical device 100 to be removed from the subject 10 when force is applied to it. Furthermore, for example, the thickness of the polymer matrix 120 and the thickness of the medical device 100, including the exposed portions of the multiple fibers 122, may facilitate the removal of the medical device 100 from the subject 10. In addition, the polymer matrix 120 may control the extent (e.g., depth) and / or degree of tissue infiltration into the medical device 100, providing further control for the removal of the medical device 100 upon completion of the procedure.

[0031] Each of the aforementioned systems, devices, assemblies, and methods may be used to fix an implantable device to target tissue with enhanced fixation. By providing the medical device with temporary and permanent mechanisms that can fix it to target tissue, instances of the device moving away from the target site can be minimized, thereby increasing the effectiveness of treating the target site. In this case, the user can reduce the overall procedure time, increase the efficiency of the procedure, and / or avoid unnecessary harm to the target body caused by subsequent procedures to reposition the device to the target site due to the device moving.

[0032] It will be apparent to those skilled in the art that various modifications and variations can be made to the disclosed apparatus and methods without departing from the scope of this disclosure. Other aspects of this disclosure will be apparent to those skilled in the art from the discussion herein and the implementation of the features disclosed herein. This specification and the examples are intended to be illustrative only.

Claims

1. A body comprising an expandable stent having a plurality of support members and a plurality of openings between adjacent support members, A polymer matrix on the main body comprising multiple fibers that define multiple pores and enable tissue growth through said pores, A silicone, which is at least partially disposed within the plurality of openings of the main body and is positioned radially between the main body and the polymer matrix, A medical device comprising a bioadhesive coating that at least partially covers the polymer matrix.

2. The medical device according to claim 1, wherein the bioadhesive coating is biodegradable.

3. The medical device according to claim 1 or 2, wherein the plurality of fibers have a diameter in the range of 300 nm to 700 nm.

4. The medical device according to any one of claims 1 to 3, wherein the bioadhesive coating is chemically bonded to the plurality of fibers.

5. The medical device according to claim 1, wherein the plurality of fibers are positioned on the plurality of support members.

6. The medical device according to any one of claims 1 to 5, wherein the plurality of fibers are electrospun onto the main body.

7. The medical device according to any one of claims 1 to 6, wherein the bioadhesive coating comprises a polysaccharide crosslinked with a linker molecule.

8. The medical device according to claim 7, wherein the polysaccharide contains chitosan.

9. The medical device according to claim 8, wherein the chitosan is crosslinked.

10. The medical device according to any one of claims 7 to 9, wherein the linker molecule contains polyethylene glycol.

11. The medical device according to any one of claims 1 to 10, wherein the polymer matrix comprises a fluoropolymer.

12. The medical device according to any one of claims 1 to 11, wherein the main body comprises a biocompatible metal or metal alloy configured to move from a compressed state to an expanded state.

13. The medical device according to claim 12, wherein in the compressed form, the body has a first length and a first diameter, and in the expanded form, the body has a second length greater than the first length and a second diameter smaller than the first diameter.

Citation Information

Patent Citations

  • Intratubal stent for installation of transplantation piece

    JP1996336597A

  • Self-expanding intraluminal stent graft

    JP1999501243A

  • Adhesive stent coating to prevent displacement

    JP2015514557A

  • Dissolvable or degradable adhesive polymers to prevent stent migration

    JP2016527051A

  • Electrospun material covered medical appliances and methods of manufacture

    US20140081414A1